Immunotherapy using 'young cells' offers promising option against cancer

A new study suggests that the age of certain immune cells used in immunotherapy plays a role in how effective it is. These cells -- natural killer (NK) cells -- appear to be more effective the earlier they are in development, opening the door to the possibility of an immunotherapy that would not utilize cells from the patient or a matched donor. Instead, they could be developed from existing supplies of what are called human pluripotent stem cells.